Protara Therapeutics (TARA) EBITDA (2013 - 2026)

Protara Therapeutics (TARA) has reported EBITDA for 14 consecutive years, with -$19.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBITDA fell 38.98% year-over-year to -$19.6 million; the TTM figure through Mar 2026 stood at -$70.1 million (down 36.22% YoY), while the FY2025 annual figure was -$64.5 million, down 31.32% from the prior year.
• EBITDA declined to -$19.6 million in Q1 2026 per TARA's latest filing, from -$19.1 million in the prior quarter.
• Across five years, EBITDA topped out at -$8.0 million in Q3 2022 and bottomed at -$39.5 million in Q4 2022.
• Historically, EBITDA has averaged -$14.4 million across 5 years, with a median of -$12.1 million in 2023.
• Annual changes were most pronounced in 2022 — EBITDA slumped 284.07% — and 2023, when it jumped 72.05%.
• Protara Therapeutics' EBITDA stood at -$39.5 million in 2022, then surged by 72.05% to -$11.0 million in 2023, then declined by 29.63% to -$14.3 million in 2024, then tumbled by 33.31% to -$19.1 million in 2025, then retreated by 2.88% to -$19.6 million in 2026.
• Business Quant data shows TARA's EBITDA at -$19.6 million in Q1 2026, -$19.1 million in Q4 2025, and -$14.8 million in Q3 2025.